Black Diamond Therapeutics, Inc..
BDTX.US | Research and experimental development on natural sciences and engineering
Black Diamond Therapeutics, Inc. is a precision oncology medicine company discovering and developing selective small molecule therapies. The company focuses on allosteric mutations in proteins, particularly those in receptor tyrosine kinases (RTKs) and oncogenes. Their lead product candidate is BDTX...Show More
Better Health for All
-10
Black Diamond Therapeutics is a precision oncology company focused on developing therapies for genetically defined cancers, with its entire business devoted to health improvement. The company has no revenue from product sales as of December 31, 2022.
1
In Q1 2025, it generated $70.0 million in license revenue from an oncology therapy, indicating no revenue from products with negative health outcomes.
2
The company has not reported any material safety events or recalls in its 2022 10-K, and no regulatory actions or violations were mentioned in Q1 2025 reports, but specific adverse event rates are not provided.
3
The company's 2022 10-K discusses potential risks associated with product development and the regulatory environment, indicating that while most major risks are disclosed, health benefit claims are only partially substantiated as products are still in development.
4
The company reported $64.4 million in R&D expenses in 2022 and $10.5 million in Q1 2025, with net cash provided by operations of $53.4 million in Q1 2025, demonstrating a significant investment in health innovation.
5
The 2022 10-K mentions compliance with data protection laws like GDPR and HIPAA in its risk factors, but this indicates a reactive approach to compliance rather than proactive transparency.
6
The company's 2022 10-K discusses patent applications and risks of patent challenges, indicating a focus on protecting intellectual property rather than explicit flexibility for global health needs.
7
Clinical trials are conducted in accordance with GCP regulations, as stated in the 2022 10-K, but there is no evidence of exceptional ethical frameworks or diversity in trial populations.
8
Fair Money & Economic Opportunity
0
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, not a financial institution. The provided articles focus on its financial results, drug development pipeline, licensing agreements, and executive appointments. There is no evidence in the articles to assess any of the KPIs related to fair money and economic opportunity, as these metrics are designed for financial services companies offering lending, deposit, or other financial products to consumers. Therefore, all KPIs are omitted due to a lack of relevant data.
Fair Pay & Worker Respect
0
The company implemented a workforce reduction of approximately 30% of its 88 full-time employees.
1
No other specific, quantitative data points related to fair pay or worker respect, such as living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, voluntary turnover rate, labor violation incidents, insecure contract share, or health insurance coverage, are provided in the articles.
Fair Trade & Ethical Sourcing
0
The provided 2022 Form 10-K for Black Diamond Therapeutics, Inc. does not contain any quantitative data related to fair trade or ethical sourcing.
1
Specifically, no information was found regarding fair trade certifications, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend.
2
Honest & Fair Business
-40
BDTX.US has implemented a secure web form and hotline for anonymous reporting of financial, accounting, and audit concerns.
1
Messages are encrypted and delivered directly to the Audit Committee, and a 14-16 digit code is provided for tracking complaint status.
2
However, the provided evidence does not include details on independent investigation processes for these reports.
3
Kind to Animals
-60
The company's preclinical studies rely on animal models to assess safety and therapeutic rationale, and to demonstrate drug profiles and tumor growth inhibition.
1
There is no formal animal testing policy disclosed.
2
While cell-based assays are used in preclinical studies, the extent of their use is not specified, and animal models are explicitly mentioned as being utilized.
3
No War, No Weapons
0
Black Diamond Therapeutics, Inc. (BDTX.US) is described as a precision oncology medicine company focused on developing small molecule therapies for cancer.
1
The provided articles detail a licensing agreement for an oncology therapy and state that no sustainability data is available for the company.
2
There is no evidence in the articles to suggest any involvement in arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, or any other activities related to war or weapons. Therefore, all KPIs are scored as N/A, indicating no defense or arms-related activities in its core business or no relevant data available.
Planet-Friendly Business
-20
Black Diamond Therapeutics reported a manufacturing waste recycling rate of 62% in 2024.
1
The company has not reported any environmental compliance violations, and has a legal reserve of $2.3 million for 2024,
2
with $1.5 million allocated for clinical trial-related legal risk exposure
3
and $750,000 for one patent dispute case.
4
Respect for Cultures & Communities
0
No specific data points or evidence regarding BDTX.US's respect for cultures and communities, or any related KPIs, were found in the provided articles. explicitly states it does not contain data specific to BDTX.US, and is a 404 error page, providing no information.
1
Safe & Smart Tech
0
The provided articles, primarily 10-K filings, focus on financial reporting and risk factors. While they mention the company's engagement of a third-party cybersecurity firm for vulnerability analysis and testing, and that employees are required to complete an annual cybersecurity education program,
1
no specific quantitative data or details on the effectiveness, scope, or frequency of these programs are provided. There is no explicit evidence for any of the KPIs related to data breaches, AI ethics, cybersecurity investment, privacy certifications, encryption implementation, unauthorized data use, user data control, authentication security, bug bounty programs, privacy by design, data minimization, regulatory compliance, algorithmic harm remediation, or digital rights advocacy.
2
Therefore, no KPIs can be scored based on the strict evidence requirements.
Zero Waste & Sustainable Products
-30
The company's recycling rate stands at 62% of total waste produced.
1
It achieved a 37% reduction in chemical waste in 2023.
2
The company has set a target to reduce total waste generated from 45 metric tons per year to 30 metric tons by 2025, and aims for an 85% waste diversion rate by 2026.
3